New gel could help cancer patients ditch steroid creams
NCT ID NCT04087629
First seen Jun 25, 2026 · Last updated Sep 11, 2026 · Updated 2 times
Summary
This study is testing whether a special gel called StrataCTX can help people with skin reactions from cutaneous T-cell lymphoma (CTCL) or cancer treatments use less steroid cream. Steroid creams can have side effects when used a lot, so finding an alternative is important. The study will enroll 70 adults and measure itching and quality of life over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- StrataCTX gel (a flexible wound dressing)
- What this could lead to
- If it works, this could offer a way to manage skin reactions with less reliance on steroid creams, potentially reducing side effects from long-term steroid use.
- What could go wrong
- This is an early, small study (70 people) without a comparison group, so results may not be conclusive. The gel is a device, not a drug, so its effect may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2021
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Ability to sign informed consent document * Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel * Patients with a diagnosis of CTCL who have intractable pruritis * Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief * Patients on chemo/immunotherapy with drug induced rash Exclusion Criteria: * Patients currently undergoing radiotherapy * Patients currently receiving oral steroids * Patients who are unable to apply topical medications
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CTCL are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.